Recent advances in design of glycogen phosphorylase inhibitors

Current Enzyme Inhibition

Volumn 7, Issue 4, 2011, Pages 259-267

  Li, Wen Liang ^a   Jian, Chen ^a   Luo, Mei Hong ^a   Han, Lü ^a   Li, Ma ^a   Li, Wei Lin ^a  

^a INSTITUTE OF BOTANY   (China)

Author keywords

Binding sites; Glycogen phosphory lase; Inhibitors; Type 2 diabetes

Indexed keywords

ADENOSINE PHOSPHATE; ANTIDIABETIC AGENT; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOSTERISM; DRUG BINDING SITE; DRUG EFFECT; DRUG STRUCTURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 84863342432     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/157340811799860533     Document Type: Review

References (57)

1. Cori, C. F.; Cori, G. T. Mechanism of formation of hexosemonophosphate in muscle and isolation of a new phosphate ester. Proc. Soc. Exp. Biol. Med., 1936, 34, 702-705.
2. Martin, W. H.; Hoover, D. J.; Armento, S. J.; Stock, I. A.; McPherson, R. K.; Danley, D. E.; Stevenson, R. W.; Barrett, E. J.; Treadway, J. L. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. USA, 1998, 95, 1776-1781.
3. Barford, D.; Johnson, L. N. The allosteric transition of glycogen phosphorylase. Nature, 1989, 340, 609-616.
4. Baker, D. J.; Timmons, J. A.; Greenhaff, P. L. Glycogen phosphorylase inhibition in type 2 diabetes therapy. Diabetes, 2005, 54, 2453-2459.
5. Treadway, J. L.; Mendys, P.; Hoover, D. J. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs, 2001, 10, 439-454.
6. N.G., O. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. Curr. Protein Peptide Sci., 2002, 3, 561-586.
7. Sprang, S. R.; Acharya, K. R.; Goldsmith, E. J.; Stuart, D. I.; Varvill, K.; Fletterick, R. J.; Madsen, N. B.; Johnson, L. N. Structural changes in glycogen phosphorylase induced by phosphorylation. Nature, 1988, 336, 215-221.
8. Sprang, S. R.; Goldsmith, E. J.; Fletterick, R. J.; Withers, S. G.; Madsen, N. B. Catalytic site of glycogen phosphorylase: structure of the T state and specificity for.alpha.-D-glucose. Biochemistry (Mosc), 1982, 21, 5364-5371.
9. Oikonomakos, N. G.; Schnier, J. B.; Zographos, S. E.; Skamnaki, V. T.; Tsitsanou, K. E.; Johnson, L. N. Flavopiridol Inhibitsglycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem., 2000, 275, 34566-34573.
10. Johnson, L. Glycogen phosphorylase: control by phosphorylation and allosteric effectors. FASEB J., 1992, 6, 2274-2282.
11. Oikonomakos, N. G.; Skamnaki, V. T.; Tsitsanou, K. E.; G Gavalas, N.; Johnson, L. N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure (London, England: 1993), 2000, 8, 575-584.
12. Johnson, L. N.; Jenkins, J. A.; Wilson, K. S.; Stura, E. A.; Zanotti, G. Proposals for the catalytic mechanism of glycogen phosphorylase b prompted by crystallographic studies on glucose 1-phosphate binding. J. Mol. Biol., 1980, 140, 565-580.
13. Rath, V. L.; Ammirati, M.; Danley, D. E.; Ekstrom, J. L.; Gibbs, E. M.; Hynes, T. R.; Mathiowetz, A. M.; McPherson, R. K.; Olson, T.V.; Treadway, J. L.; Hoover, D. J. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol., 2000, 7, 677-682.
14. Lukacs, C. M.; Oikonomakos, N. G.; Crowther, R. L.; Hong, L.-N.; Kammlott, R. U.; Levin, W.; Li, S.; Liu, C.-M.; Lucas-McGady, D.; Pietranico, S.; Reik, L. The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: An intermediate conformation with T-state and R-state features. Proteins: Structure, Function, and Bioinformatics, 2006, 63, 1123-1126.
15. Somsak, L.; Nagy, V.; Hadady, Z.; Docsa, T.; Gergely, P. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments. Curr. Pharm. Des., 2003, 9, 1177-1189.
16. Martin, J. L.; Veluraja, K.; Ross, K.; Johnson, L. N.; Fleet, G. W. J.; Ramsden, N. G.; Bruce, I.; Orchard, M. G.; Oikonomakos, N. G. Glucose analog inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry (Mosc), 1991, 30, 10101-10116.
17. Wen, X.; Sun, H.; Liu, J.; Cheng, K.; Zhang, P.; Zhang, L.; Hao, J.; Zhang, L.; Ni, P.; Zographos, S. E.; Leonidas, D. D.; Alexacou, K.-M.; Gimisis, T.; Hayes, J. M.; Oikonomakos, N. G. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and Xraycrystallographic studies. J. Med. Chem., 2008, 51, 3540-3554.
18. Wright, S. W.; Rath, V. L.; Genereux, P. E.; Hageman, D. L.; Levy, C. B.; McClure, L. D.; McCoid, S. C.; McPherson, R. K.; Schelhorn, T. M.; Wilder, D. E.; Zavadoski, W. J.; Gibbs, E. M.; Treadway, J. L. Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Bioorg. Med. Chem. Lett., 2005, 15, 459-465.
19. Somsak, L.; Czifrak, K.; Toth, M.; Bokor, E.; Chrysina, E. D.; Alexacou, K. M.; Hayes, J. M.; Tiraidis, C.; Lazoura, E.; Leonidas, D. D.; Zographos, S. E.; Oikonomakos, N. G. New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr. Med. Chem., 2008, 15, 2933-2983.
20. Oikonomakos, N. G.; Somsak, L. Advances in glycogen phosphorylase inhibitor design. Curr. Opin. Investig. Drugs, 2008, 9, 379-395.
21. Buchbinder, J. L.; Guinovart, J. J.; Fletterick, R. J. Mutations in paired.alpha.-helixes at the subunit interface of glycogen phosphorylase alter homotropic and heterotropic cooperativity. Biochemistry (Mosc), 1995, 34, 6423-6432.
22. Fletterick, R. J.; Madsen, N. B. The structures and related functions of phosphorylase a. Annu. Rev. Biochem., 1980, 49, 31-61.
23. Newgard, C. B.; Littman, D. R.; van Genderen, C.; Smith, M.; Fletterick, R. J. Human brain glycogen phosphorylase. Cloning, sequence analysis, chromosomal mapping, tissue expression, and comparison with the human liver and muscle isozymes. J. Biol. Chem., 1988, 263, 3850-3857.
24. Ekstrom, J. L.; Pauly, T. A.; Carty, M. D.; Soeller, W. C.; Culp, J.; Danley, D. E.; Hoover, D. J.; Treadway, J. L.; Gibbs, E. M.; Fletterick, R. J.; Day, Y. S. N.; Myszka, D. G.; Rath, V. L. Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Chem. Biol., 2002, 9, 915-924.
25. Fletterick, R. J.; Sprang, S. R. Glycogen phosphorylase structures and function. Accounts Chem. Res., 1982, 15, 361-369.
26. Goldsmith, E. J.; Sprang; Hamlin, R.; Xuong, N. H.; Fletterick, R. J. Domain separation in the activation of glycogen phosphorylase a. Science, 1989, 245, 528-532.
27. Henke, B. R.; Sparks, S. M. Glycogen phosphorylase inhibitors. Mini-Rev. Med. Chem., 2006, 6, 845-857.
28. Felföldi, N.; Tóth, M.; Chrysina, E. D.; Charavgi, M.-D.; Alexacou, K.-M.; Somsák, L. Synthesis of new glycosyl biuret and urea derivatives as potential glycoenzyme inhibitors. Carbohydr. Res., 2010, 345, 208-213.
29. Czakó, Z.; Juhász, L.; Kenéz, Á.; Czifrák, K.; Somsák, L.; Docsa, T.; Gergely, P.; Antus, S. Synthesis and glycogen phosphorylase inhibitory activity of N-([beta]-d-glucopyranosyl)amides possessing 1,4-benzodioxane moiety. Bioorg. Med. Chem., 2009, 17, 6738-6741.
30. Jeon, C. Y.; Murray, M. B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med., 2008, 5, e152.
31. Bisht, S. S.; Fatima, S.; Tamrakar, A. K.; Rahuja, N.; Jaiswal, N.; Srivastava, A. K.; Tripathi, R. P. Synthetic studies in butenonyl Cglycosides: Preparation of polyfunctional alkanonyl glycosides and their enzyme inhibitory activity. Bioorg. Med. Chem. Lett., 2009, 19, 2699-2703.
32. Somsák, L.; Kovács, L.; Tóth, M.; Osz, E.; Szilágyi, L.; Györgydeák, Z.; Dinya, Z.; Docsa, T.; Tóth, B.; Gergely, P. Synthesis of and a comparative study on the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of d-glucoand d-xylopyranosylidene-spiro-(thio)hydantoins and N-(dglucopyranosyl) amides. J. Med. Chem., 2001, 44, 2843-2848.
33. Chrysina, E. D.; Oikonomakos, N. G.; Zographos, S. E.; Kosmopoulou, M. N.; Bischler, N.; Leonidas, D. D.; Kovács, L.; Docsa, T.; Gergely, P.; Somsák, L. Crystallographic studies on α- and β-D-glucopyranosyl formamide analogues, inhibitors of glycogen phosphorylase. Biocatal. Biotransform., 2003, 21, 233-242.
34. Watson, K. A.; Mitchell, E. P.; Johnson, L. N.; Cruciani, G.; Son, J. C.; Bichard, C. J. F.; Fleet, G. W. J.; Oikonomakos, N. G.; Kontou, M.; Zographos, S. E. Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. Acta Crystallographica Section D., 1995, 51, 458-472.
35. Oikonomakos, N. G.; Kosmopoulou, M.; Zographos, S. E.; Leonidas, D. D.; Chrysina, E. D.; Somsák, L.; Nagy, V.; Praly, J.- P.; Docsa, T.; Tóth, B.; Gergely, P. Binding of N-acetyl-N′-β-dglucopyranosyl urea and N-benzoyl-N′-β-d-glucopyranosyl urea to glycogen phosphorylase b. Eur. J. Biochem., 2002, 269, 1684-1696.
36. Deng, Q.; Lu, Z.; Bohn, J.; Ellsworth, K. P.; Myers, R. W.; Geissler, W. M.; Harris, G.; Willoughby, C. A.; Chapman, K.; McKeever, B.; Mosley, R. Modeling aided design of potent glycogen phosphorylase inhibitors. J. Mol. Graph. Model., 2005, 23, 457-464.
37. Bergans, N.; Stalmans, W.; Goldmann, S.; Vanstapel, F. Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite. Diabetes, 2000, 49, 1419-1426.
38. Oikonomakos, N. G.; Tsitsanou, K. E.; Zographos, S. E.; Skamnaki, V. T.; Goldmann, S.; Bischoff, H. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3- isopropyl 4-(2-chlorophenyl)-1,4-dihydro- 1-ethyl-2-methylpyridine- 3,5,6-tricarboxylate. Protein Sci., 1999, 8, 1930-1945.
39. Klabunde, T.; Wendt, K. U.; Kadereit, D.; Brachvogel, V.; Burger, H.-J.; Herling, A. W.; Oikonomakos, N. G.; Kosmopoulou, M. N.; Schmoll, D.; Sarubbi, E.; von Roedern, E.; Schönafinger, K.; Defossa, E. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48, 6178-6193.
40. Wen, X.; Sun, H.; Liu, J.; Wu, G.; Zhang, L.; Wu, X.; Ni, P. Pentacyclic triterpenes. Part 1: The first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases. Bioorg. Med. Chem. Lett., 2005, 15, 4944-4948.
41. Ogawa, A. K.; Willoughby, C. A.; Bergeron, R.; Ellsworth, K. P.; Geissler, W. M.; Myers, R. W.; Yao, J.; Harris, G.; Chapman, K. T. Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 3405-3408.
42. Anderka, O.; Loenze, P.; Klabunde, T.; Dreyer, M. K.; Defossa, E.; Wendt, K. U.; Schmoll, D. Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors. Biochemistry (Mosc), 2008, 47, 4683-4691.
43. Soman, G.; Philip, G. The nature of the binding site for aromatic compounds in glycogen phosphorylase b. Biochem. J., 1975, 147,369.
44. Kasvinsky, P. J.; Madsen, N. B.; Sygusch, J.; Fletterick, R.J. The regulation of glycogen phosphorylase alpha by nucleotide derivatives. Kinetic and x-ray crystallographic studies. J. Biol. Chem., 1978, 253, 3343-3351.
45. Madsen, N. B.; Shechosky, S.; Fletterick, R. J. Site-site interactions in glycogen phosphorylase b probed by ligands specific for each site. Biochemistry (Mosc), 1983, 22, 4460-4465.
46. Sprang, S.; Fletterick, R.; Stern, M.; Yang, D.; Madsen, N.; Sturtevant, J. Analysis of an allosteric binding site: the nucleoside inhibitor site of phosphorylase a. Biochemistry (Mosc), 1982, 21, 2036-2048.
47. Oikonomakos, N. G.; Schnier, J. B.; Zographos, S. E.; Skamnaki, V. T.; Tsitsanou, K. E.; Johnson, L. N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem., 2000, 275, 34566-34573.
48. Hampson, L. J.; Arden, C.; Agius, L.; Ganotidis, M.; Kosmopoulou, M. N.; Tiraidis, C.; Elemes, Y.; Sakarellos, C.; Leonidas, D. D.; Oikonomakos, N. G. Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site. Bioorg. Med. Chem., 2006, 14, 7835-7845.
49. Hayes, J. M.; Leonidas, D. D. Computation as a tool for glycogen phosphorylase inhibitor design. Mini Rev. Med. Chem., 2010, 10, 1156-1174.
50. Loughlin, W. A. Recent advances in the allosteric inhibition of glycogen phosphorylase. Mini Rev. Med. Chem., 2010, 10, 1139-1155.
51. Oikonomakos, N. G.; Zographos, S. E.; Skamnaki, V. T.; Archontis, G. The 1.76 Å resolution crystal structure of glycogen phosphorylase b complexed with glucose, and CP320626, a potential antidiabetic drug. Bioorg. Med. Chem., 2002, 10, 1313-1319.
52. Rosauer, K. G.; Ogawa, A. K.; Willoughby, C. A.; Ellsworth, K. P.; Geissler, W. M.; Myers, R. W.; Deng, Q.; Chapman, K. T.; Harris, G.; Moller, D. E. Novel 3,4-dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a. Bioorg. Med. Chem. Lett., 2003, 13, 4385-4388.
53. Hoover, D. J.; Lefkowitz-Snow, S.; Burgess-Henry, J. L.; Martin, W. H.; Armento, S. J.; Stock, I. A.; McPherson, R. K.; Genereux, P. E.; Gibbs, E. M.; Treadway, J. L. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem., 1998, 41, 2934-2938.
54. Prathipati, P.; Pandey, G.; Saxena, A. K. Co MFA and docking studies on glycogen phosphorylase a inhibitors as antidiabetic agents. J. Chem. Inf. Model., 2005, 45, 136-145.
55. Wright, S. W.; Rath, V. L.; Genereux, P. E.; Hageman, D. L.; Levy, C. B.; McClure, L. D.; McCoid, S. C.; McPherson, R. K.; Schelhorn, T. M.; Wilder, D. E.; Zavadoski, W. J.; Gibbs, E. M.; Treadway, J. L. Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-raycrystallographic characterization. Bioorg. Med. Chem. Lett., 2005, 15, 459-465.
56. Martin, W. H.; Hoover, D. J.; Armento, S. J.; Stock, I. A.; McPherson, R. K.; Danley, D. E.; Stevenson, R. W.; Barrett, E. J.; Treadway, J. L. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. USA, 1998, 95, 1776-1781.
57. Pinotsis, N.; Leonidas, D. D.; Chrysina, E. D.; Oikonomakos, N. G.; Mavridis, I. M. The binding of beta- and gamma-cyclodextrins to glycogen phosphorylase b: kinetic and crystallographic studies. Protein Sci., 2003, 12, 1914-1924.